GAITHERSBURG, Md., June 1, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the Jefferies Global Healthcare Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Thursday, June 8, 2023 | |||||
Time: | 9:00 – 9:25 a.m. Eastern Daylight Time (EDT) | |||||
Location: | New York, NY | |||||
Moderator: | Roger Song, M.D., CFA, Equity Research Analyst – Biotechnology | |||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research and Development | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Thursday, June 8, 2023 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events and Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.00 |
| Daily Change: | -0.20 -3.23 |
| Daily Volume: | 4,284,894 |
| Market Cap: | US$961.080M |
April 15, 2025 March 11, 2025 February 27, 2025 December 13, 2024 December 10, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
